Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers (NYSE:HIMS) has launched an online GLP-1 supply tracker where people can share information about where the ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

Analysts are buzzing as well, with TD Cowen raising its price target to $28, citing HIMS' diverse revenue streams and minimal ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...